bioAffinity Technologies, Inc. (BIAF): Findings report on ability to measure cellular and soluble inflammatory protein biomarkers in sputum, including biologic drug targets

bioAffinity Technologies (BIAF) reported 235 CyPath Lung tests in October, a 29% increase from last year. The company attributes growth to expanded physician adoption and commercial efforts. CyPath Lung uses AI to assess lung cancer risk, with 92% sensitivity and 87% specificity in trials. BIAF is also advancing R&D for asthma, COPD, and skin cancer treatments.

bioAffinity Technologies (BIAF) reported Q3 EPS of -$5.89, beating estimates by $25.61, but revenue of $1.1M missed expectations of $1.91M. The stock is down 63.06% over 3 months and 91.21% over 12 months, with a 'weak performance' financial health score according to InvestingPro.

bioAffinity Technologies reported Q3 2026 revenue of $1.1M and a net loss of $5.3M. CyPath Lung test sales doubled year-to-date, with testing revenue up 79%. The company had $2.6M in cash at quarter-end. Operating loss widened to $3.5M from $2.3M a year earlier. Physician orders and test reports increased significantly, and the company expanded its distribution network and research collaborations.

bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release bioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath ® Lung Commercialization CyPath ® Lung test unit sales double year to date over 2025, with solid gains in physician utilization and recurring orders; testing rev

bioAffinity Technologies (BIAF) will present CyPath Lung at CHEST 2026, highlighting its use in lung cancer risk assessment and new asthma/COPD inflammation test research. The company reported 92% sensitivity, 87% specificity, and 99% NPV in prior trials. The Medical and Scientific Advisory Board will discuss expansion and R&D programs.

bioAffinity Technologies will present data at CHEST 2026 on its investigational sputum test, which can detect lung inflammation protein biomarkers linked to asthma and COPD drug targets. The test, not yet FDA cleared, measures biomarkers like TSLP and IL-5, building on the company's CyPath Lung platform. According to the SEC filing, the test may help identify patients for biologic therapies with further validation.